Rheumatology
Conference Coverage
IBD risk ‘uncertain’ in biologic-treated AxSpA patients
“Enormous uncertainty” surrounds the risk of inflammatory bowel disease associated with biologic treatment in patients with axial...
From the Journals
Secukinumab’s antipsoriatic effects confirmed in U.S. patient population
Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in...
Conference Coverage
OARSI sets sights on classifying early-stage knee OA
“Early-stage knee OA classification criteria, we believe are critically required,” Gillian Hawker, MD, MSc, said at the OARSI 2022 World Congress...
News from the FDA/CDC
U.S. FDA warns of hidden drug ingredients in certain supplements products
The products are marketed to treat arthritis, muscle pain and other conditions and are sold online and in some retail stores with variations of...
Latest News
Restrictive, vegan-based diet linked to fewer RA symptoms
A small, randomized, crossover study suggests a vegan diet improves joint pain in rheumatoid arthritis, but the findings are unclear.
Conference Coverage
Inadequate pain relief in OA, high opioid use before TKA
Rates of inadequate pain relief in knee and hip OA, and high opioid use before total knee replacement surgery were reported in separate studies at...
Conference Coverage
Weight gain may exacerbate structural damage in knee OA
Weight changes can have a significant effect on the structural progression of knee OA, according to new findings from Osteoarthritis Initiative...
Latest News
Hypocaloric diet controls joint activity in psoriatic arthritis – regardless of weight loss
A hypocaloric diet in patients with psoriatic arthritis improved disease activity and body composition.
Conference Coverage
High comorbidity rate seen before osteoarthritis diagnosis
More than 40 medical conditions were positively associated with having a new diagnosis of osteoarthritis in a large, nested case-control study.
From the Journals
Denosumab boosts bone strength in glucocorticoid users
Compared with risedronate, denosumab promoted bone strength in patients initiating glucocorticoids and those on long-term therapy.
From the Journals
TNF inhibitor treatment models promote personalized care in ankylosing spondylitis
A retrospective cohort study of 10 randomized, controlled trials showed the ability of baseline variables to predict response to tumor necrosis...